Results 291 to 300 of about 519,424 (350)

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

Advanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian, Sreenidhi Mohanvelu, Sheeja Aravindan, Afsana Parveen Jahir Hussain, Sivasubramani Narayanan, Sabir Salim, Loganayaki Periyasamy, Natarajan Aravindan   +7 more
wiley   +1 more source

Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to overcoming tyrosine kinase inhibitor resistance. [PDF]

Bioimpacts
Singh D, Kumar A, Sharma VV.
europepmc   +1 more source

Anti-cancer activity of EGF receptor-tyrosine kinase inhibitors in human non-small lung cancer cells

, 2013
Ho Viet Anh
openalex   +1 more source

Supplementary Material for: Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review

figshare admin karger, Gameil A., Ghasoub R., Nasrin Jafari, Shafei L., Benkhadra M., Laws S., H. A. Hamad, Sabet I., Milojkovic D., Fernyhough L.   +10 more
openalex   +1 more source

Genetic Control of Tissue Remodeling by a Non‐Coding SNP in ITGA8 Explains Carotenoid‐Based Color Polymorphism in Marine Mollusks

Advanced Science, EarlyView.
In this study, the orange‐muscle giant abalone (Haliotis gigantea) is used as a model to identify a non‐coding SNP that disrupts the interaction between ITGA8 pre‐mRNA and the splicing factor ILF2, leading to altered ITGA8 splicing. These splicing changes promote carotenoid accumulation in abalone muscle through the regulation of tissue remodeling ...
Xiaohui Wei, Wenzhu Peng, Zekun Huang, Bingye Yang, Yiyu Wu, Minzhen Han, Yi Wang, Bingling Peng, Guosheng Hu, Jiawei Hong, Guijia Liu, Linwei Nie, Yang Gan, Miaoqin Huang, Xuan Luo, Weiwei You, Wen Liu, Caihuan Ke   +17 more
wiley   +1 more source

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Gonzalez-Ericsson PI, Unni N, Jhaveri K, Stringer-Reasor E, Liu Q, Wang Y, Sanchez V, Garcia G, Sanders ME, Lehmann BD, Balko JM, Park B, Rexer BN, Mayer IA, Arteaga CL.   +14 more
europepmc   +1 more source

254 Tyrosine kinase inhibitors

European Journal of Cancer Supplements, 2009
openaire   +1 more source

The spleen tyrosine kinase inhibitor entospletinib resolves inflammation to promote repair following acute kidney injury. [PDF]

JCI Insight
Elias EE, Lau A, Belay SG, Derakhshani A, Andonegui G, Jenne CN, Dufour A, Bracey NA, Chun J, Muruve DA.   +9 more
europepmc   +1 more source

EMP3 is upregulated upon epithelial-mesenchymal transition and contributes to EGFR-tyrosine kinase inhibitor resistance in lung adenocarcinoma. [PDF]

Eur J Med Res
Wang C, Xiong M, Zhu Y, Li K, Ni J.
europepmc   +1 more source

Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC. [PDF]

JTO Clin Res Rep
Scaglione IM, Avancini A, Eccher S, Borsati A, Pasqualin L, La Cava G, Trestini I, Tregnago D, Sposito M, Insolda J, Giannarelli D, Milella M, Pilotto S, Belluomini L.   +13 more
europepmc   +1 more source